Imatinib mesylate for the treatment of chronic myeloid leukemia

References

• Sawyers CL. Chronic myeloid leukemia. N. Engl. J. Med.340(17), 1330–1340 (1999).
   PubMed Web of Science ®Google Scholar
• Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature243(5405), 290–293 (1973).
   PubMed Web of Science ®Google Scholar
• Bartram CR, de Klein A, Hagemeijer A et al. Translocation of c-Abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature306, 277–280 (1983).
   PubMed Web of Science ®Google Scholar
• Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science247(4946), 1079–1082 (1990).
   PubMed Web of Science ®Google Scholar
• Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science247(4944), 824–830 (1990).
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Faderl S, O’Brien S. Chronic myelogenous leukemia: a review and update of therapeutic strategies. Cancer98, 427–456 (2003).
   Google Scholar
• Hehlmann R, Heimpel H, Hasford J et al. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. Blood82(2), 398–407 (1993).
   PubMed Web of Science ®Google Scholar
• Talpaz M, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU. Interferon-a produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. Ann. Intern. Med.114(7), 532–538 (1991).
   PubMed Web of Science ®Google Scholar
• Hehlmann R, Heimpel H, Hasford J et al. Randomized comparison of interferon-a with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood84(12), 4064–4077 (1994).
   PubMed Web of Science ®Google Scholar
• Interferon α-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. N. Engl. J. Med.330(12), 820–825 (1994).
   PubMed Web of Science ®Google Scholar
• Guilhot F, Chastang C, Michallet M et al. Interferon α-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N. Engl. J. Med.337(4), 223–229 (1997).
   PubMed Web of Science ®Google Scholar
• Baccarani M, Rosti G, de Vivo A et al. A randomized study of interferon-α versus interferon-α and low-dose arabinosyl cytosine in chronic myeloid leukemia. Blood99(5), 1527–1535 (2002).
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Talpaz M, Giles FJ et al. Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-α-2b and low-dose cytosine arabinoside. Cancer97(12), 3010–3016 (2003).
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Smith TL, O’Brien S, Beran M, Pierce S, Talpaz M. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-a therapy. The Leukemia Service. Ann. Intern. Med.122(4), 254–261 (1995).
   PubMed Web of Science ®Google Scholar
• Bonifazi F, de Vivo A, Rosti G et al. Chronic myeloid leukemia and interferon-α: a study of complete cytogenetic responders. Blood98(10), 3074–3081 (2001).
   PubMed Web of Science ®Google Scholar
• Gratwohl A, Brand R, Apperley J et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica91(4), 513–521 (2006).
   PubMed Web of Science ®Google Scholar
• Nagar B, Bornmann WG, Pellicena P et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res.62(15), 4236–4243 (2002).
   PubMed Web of Science ®Google Scholar
• Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science289(5486), 1938–1942 (2000).
   PubMed Web of Science ®Google Scholar
• Cowan-Jacob SW, Guez V, Fendrich G et al. Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment. Mini Rev. Med. Chem.4(3), 285–299 (2004).
   PubMed Web of Science ®Google Scholar
• Shah NP, Nicoll JM, Nagar B et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell2(2), 117–125 (2002).
   PubMed Web of Science ®Google Scholar
• Druker BJ, Tamura S, Buchdunger E et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med.2(5), 561–566 (1996).
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C, le Coutre P, Mologni L et al. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol. Dis.23(3), 380–394 (1997).
   PubMed Web of Science ®Google Scholar
• Deininger MW, Goldman JM, Lydon N, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood90(9), 3691–3698 (1997).
   PubMed Web of Science ®Google Scholar
• Cohen MH, Williams G, Johnson JR et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin. Cancer Res.8(5), 935–942 (2002).
   PubMed Web of Science ®Google Scholar
• Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med.344(14), 1031–1037 (2001).
   PubMed Web of Science ®Google Scholar
• Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin. Pharmacokinet.44(9), 879–894 (2005).
   PubMed Web of Science ®Google Scholar
• O’Brien SG, Guilhot F, Larson RA et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med.348(11), 994–1004 (2003).
   PubMed Web of Science ®Google Scholar
• Hahn EA, Glendenning GA, Sorensen MV et al. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon a plus low-dose cytarabine: results from the IRIS Study. J. Clin. Oncol.21(11), 2138–2146 (2003).
   PubMed Web of Science ®Google Scholar
• Druker BJ, Guilhot F, O’Brien SG et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med.355(23), 2408–2417 (2006).
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Druker B, Larson RA, O’Brien SG, Gathmann I, Guilhot F. IRIS 6-year follow-up: sustained survival and declining annual rate of transformation in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. 2007 ASH Annual Meeting (2007).
   Google Scholar
• Gorre ME, Mohammed M, Ellwood K et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science293(5531), 876–880 (2001).
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Kreil S, Corbin AS et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia16(11), 2190–2196 (2002).
   PubMed Web of Science ®Google Scholar
• von Bubnoff N, Schneller F, Peschel C, Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet359, 487–491 (2002).
   PubMed Web of Science ®Google Scholar
• Branford S, Rudzki Z, Walsh S et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood99(9), 3472–3475 (2002).
   PubMed Web of Science ®Google Scholar
• Soverini S, Martinelli G, Rosti G et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J. Clin. Oncol.23(18), 4100–4109 (2005).
   PubMed Web of Science ®Google Scholar
• Soverini S, Colarossi S, Gnani A et al. Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin. Cancer Res.12(24), 7374–7379 (2006).
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Talpaz M, O’Brien S et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood103(8), 2873–2878 (2004).
   PubMed Web of Science ®Google Scholar
• Castagnetti F, Amabile M, Palandri F et al. Imatinib high dose (800 mg) in intermediate sokal risk patients CML in chronic phase: results of a Phase II trial of the GIMEMA CML working party. Haematologica92(Suppl. 2), 205 (2007). (Abstract 0550)
   Google Scholar
• Baccarani M, Castagnetti F, Porkka K et al. A prospective study of imatinib 400 mg vs 800 mg frontline in high risk Ph+ chronic myeloid leukemia (CML) patients. 2007 ASH Annual Meeting (2007).
   Google Scholar
• Pye SM, Cortes J, Ault P et al. The effects of imatinib on pregnancy outcome. Blood (2008) (Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Reckmann AH, Fischer T, Peng B. Effect of food on STI571 (Glivec®) pharmacokinetics and bioavailability. Proc. Am. Soc. Clin. Oncol.20, 1223 (2002). (Abstract).
   Google Scholar
• Deininger MW, O’Brien SG, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J. Clin. Oncol.21(8), 1637–1647 (2003).
   PubMed Web of Science ®Google Scholar
• Hensley ML, Ford JM. Imatinib treatment: specific issues related to safety, fertility, and pregnancy. Semin. Hematol.40(2 Suppl. 2), 21–25 (2003).
   PubMed Web of Science ®Google Scholar
• Lindahl P, Johansson BR, Leveen P, Betsholz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science277, 242–245 (1997).
   PubMed Web of Science ®Google Scholar
• Hsiao LT, Chung HM, Lin JT et al. Stevens-Johnson syndrome after treatment with STI571: a case report. Br. J. Haematol.117(3), 620–622 (2002).
   PubMed Web of Science ®Google Scholar
• Etienne G, Cony-Makhoul P, Mahon FX. Imatinib mesylate and gray hair. N. Engl. J. Med.347(6), 446 (2002).
   PubMed Web of Science ®Google Scholar
• Kerkela R, Grazette L, Yacobi R et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med.12(8), 908–916 (2006).
   PubMed Web of Science ®Google Scholar
• Rosti G, Martinelli G, Baccarani M. In reply to ‘Cardiotoxicity of the cancer therapeutic agent imatinib mesylate’. Nat. Med.13(1), 15–16 (2007).
   PubMed Web of Science ®Google Scholar
• Hatfield A, Owen S, Pilot PR. In reply to ‘Cardiotoxicity of the cancer therapeutic agent imatinib mesylate’. Nat. Med.13(1), 13, 15–16 (2007).
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C, Tornaghi L, Franceschino A, Piazza R, Corneo G, Pogliani E. In reply to ‘Cardiotoxicity of the cancer therapeutic agent imatinib mesylate’. Nat. Med.13(1), 13–16 (2007).
   PubMed Web of Science ®Google Scholar
• Atallah E, Kantarjian H, Cortes J. In reply to ‘Cardiotoxicity of the cancer therapeutic agent imatinib mesylate’. Nat. Med.13(1), 14–16 (2007).
   PubMed Web of Science ®Google Scholar
• Atallah E, Durand JB, Kantarjian H, Cortes J. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood110(4), 1233–1237 (2007).
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones DM, Larson MG, Leip EP et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation106(24), 3068–3072 (2002).
   PubMed Web of Science ®Google Scholar
• Talpaz M, Silver RT, Druker BJ et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a Phase II study. Blood99(6), 1928–1937 (2002).
   PubMed Web of Science ®Google Scholar
• Sawyers CL, Hochhaus A, Feldman E et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a Phase II study. Blood99(10), 3530–3539 (2002).
   PubMed Web of Science ®Google Scholar
• Petzer AL, Eaves CJ, Lansdorp PM, Ponchio L, Barnett MJ, Eaves AC. Characterization of primitive subpopulations of normal and leukemic cells present in the blood of patients with newly diagnosed as well as established chronic myeloid leukemia. Blood88(6), 2162–2171 (1996).
   PubMed Web of Science ®Google Scholar
• Branford S, Seymour JF, Grigg A et al. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clin. Cancer Res.13(23), 7080–7085 (2007).
   PubMed Web of Science ®Google Scholar
• Rousselot P, Huguet F, Rea D et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood109(1), 58–60 (2007).
   PubMed Web of Science ®Google Scholar
• La Rosee P, Corbin AS, Stoffregen EP, Deininger MW, Druker BJ. Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). Cancer Res.62(24), 7149–7153 (2002).
   PubMed Web of Science ®Google Scholar
• Wisniewski D, Lambek CL, Liu C et al. Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. Cancer Res.62(15), 4244–4255 (2002).
   PubMed Web of Science ®Google Scholar
• Golas JM, Arndt K, Etienne C et al. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res.63(2), 375–381 (2003).
   PubMed Web of Science ®Google Scholar
• von Bubnoff N, Veach DR, Miller WT et al. Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors. Cancer Res.63(19), 6395–6404 (2003).
   PubMed Web of Science ®Google Scholar
• Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science305(5682), 399–401 (2004).
   PubMed Web of Science ®Google Scholar
• O’Hare T, Pollock R, Stoffregen EP et al. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. Blood104(8), 2532–2539 (2004).
   PubMed Web of Science ®Google Scholar
• Golemovic M, Verstovsek S, Giles F et al. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin. Cancer Res.11(13), 4941–4947 (2005).
   PubMed Web of Science ®Google Scholar
• O’Hare T, Walters DK, Stoffregen EP et al.In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res.65(11), 4500–4505 (2005).
   PubMed Web of Science ®Google Scholar
• Kimura S, Naito H, Segawa H et al. NS-187, a potent and selective dual Bcr–Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood106(12), 3948–3954 (2005).
   PubMed Web of Science ®Google Scholar
• Wolff NC, Veach DR, Tong WP, Bornmann WG, Clarkson B, Ilaria RL Jr. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia. Blood105(10), 3995–4003 (2005).
   PubMed Web of Science ®Google Scholar
• Gumireddy K, Baker SJ, Cosenza SC et al. A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc. Natl Acad. Sci. USA102(6), 1992–1997 (2005).
   PubMed Web of Science ®Google Scholar
• Naito H, Kimura S, Nakaya Y et al.In vivo antiproliferative effect of NS-187, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor, on leukemic cells harbouring Abl kinase domain mutations. Leuk. Res.30(11), 1443–1446 (2006).
   PubMed Web of Science ®Google Scholar
• Puttini M, Coluccia AM, Boschelli F et al.In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res.66(23), 11314–11322 (2006).
   PubMed Web of Science ®Google Scholar
• Cortes J, Rousselot P, Kim DW et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood109(8), 3207–3213 (2007).
   PubMed Web of Science ®Google Scholar
• Talpaz M, Shah NP, Kantarjian H et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med.354(24), 2531–2541 (2006).
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Kantarjian HM, Baccarani M et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic phase chronic myeloid leukemia after failure of imatinib therapy. Blood109(6), 2303–2309 (2007).
   PubMed Web of Science ®Google Scholar
• Guilhot F, Apperley J, Kim DW et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood109(10), 4143–4150 (2007).
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Giles F, Wunderle L et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med.354(24), 2542–2551 (2006).
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C, Gasser M, Ahmed S, Assouline S, Scapozza L. Abl inhibitor BMS354825 binding mode in Abelson kinase revealed by molecular docking studies. Leukemia19(7), 1267–1269 (2005).
   PubMed Web of Science ®Google Scholar
• O’Hare T, Walters DK, Deininger MW, Druker BJ. AMN107: tightening the grip of imatinib. Cancer Cell7(2), 117–119 (2005).
   PubMed Web of Science ®Google Scholar
• Druker BJ, Sawyers CL, Kantarjian H et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med.344(14), 1038–1042 (2001).
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Talpaz M, O’Brien S et al. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-α: follow-up results. Clin. Cancer Res.8(7), 2177–2187 (2002).
   PubMed Web of Science ®Google Scholar
• Ottmann OG, Druker BJ, Sawyers CL et al. A Phase II study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood100(6), 1965–1971 (2002).
   PubMed Web of Science ®Google Scholar